GoodRx Holdings, Inc. (GDRX)
| Previous Close | 7.06 |
| Open | 7.00 |
| Bid | 6.79 x 100 |
| Ask | 6.85 x 100 |
| Day's Range | 6.72 - 7.09 |
| 52 Week Range | 4.14 - 9.26 |
| Volume | |
| Avg. Volume | 1,380,714 |
| Market Cap | 2.594B |
| Beta (5Y Monthly) | 1.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.14 |
| Earnings Date | Nov 07, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.53 |
Simply Wall St.High Growth Tech Stocks In The United States To Watch
Over the last 7 days, the market has remained flat, but it is up 34% over the past year with earnings expected to grow by 15% per annum over the next few years. In this context, identifying high growth tech stocks that can capitalize on these favorable conditions is crucial for investors seeking robust returns.
Business WireGoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy® (epinephrine nasal spray)
SANTA MONICA, Calif., September 26, 2024--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced it is working with ARS Pharmaceuticals, Inc. ("ARS Pharmaceuticals") to offer the lowest discounted cash price for neffy® in retail pharmacy locations. Available for purchase in-store this week, consumers who have been prescribed neffy can now access a pack of two single-use neffy devices for $199 at more than 70,000 pharmacies nationwide exclusively through Goo
Yahoo FinanceWhy Big Pharma is betting on telehealth strategies
The telehealth world is entering a new phase of vertical integration in healthcare.
